Health‐related quality of life and severity of fatigue in <scp>HIV</scp>/<scp>HCV</scp> co‐infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin

Abstract

Antiviral therapy with PEGIFN+RBV impairs physical and mental health and increases severity of fatigue, while virological response is associated with improvements in physical health and fatigue symptoms. The optimization of anemia management is essential for reducing the burden of impaired HRQL and fatigue in HIV/HCV co-infected patients receiving antiviral therapy with PEGIFN+RBV.